Targeting hematological malignancies with isoxazole derivatives

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2024

Autores

Majirská, M (Autor) Outra; Pilátová, MB (Autor) Outra; Kudlicková, Z (Autor) Outra; Vojtek, M (Autor) Outra; Diniz, C (Autor) FFUP

Revista

Título: Drug Discovery Today

Vol. 29

ISSN: 1359-6446

Editora: Elsevier

Indexação

ISI Web of Knowledge - 0 Citações

Scopus - 0 Citações

Classificação Científica

CORDIS: Ciências da Saúde

Outras Informações

ID Authenticus: P-010-YQT

DOI: 10.1016/j.drudis.2024.104059

Abstract (EN): Compounds with a heterocyclic isoxazole ring are well known for their diverse biologic activities encompassing antimicrobial, antipsychotic, immunosuppressive, antidiabetic and anticancer effects. Recent studies on hematological malignancies have also shown that some of the isoxazole-derived compounds feature encouraging cancer selectivity, low toxicity to normal cells and ability to overcome cancer drug resistance of conventional treatments. These characteristics are particularly promising because patients with hematological malignancies face poor clinical outcomes caused by cancer drug resistance or relapse of the disease. This review summarizes the knowledge on isoxazole-derived compounds toward hematological malignancies and provides clues on their mechanism(s) of action (apoptosis, cell cycle arrest, ROS production) and putative pharmacological targets (c-Myc, BET, ATR, FLT3, HSP90, CARM1, tubulin, PD-1/PD-L1, HDACs) wherever known.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 23